Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

18.26
-0.9300-4.85%
Volume:1.54M
Turnover:28.06M
Market Cap:3.41B
PE:-5.45
High:19.00
Open:18.96
Low:17.93
Close:19.19
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.77
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:4.85
PE(LYR):-5.26

Loading ...

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

THOMSON REUTERS
·
Jul 22

Stocks to Watch: Super Micro Computer, AAR, Pegasystems, Dyne Therapeutics, Weatherford

Dow Jones
·
Jul 22

Dyne Therapeutics $300M Spot Secondary; price range $20.00-$21.50

TIPRANKS
·
Jul 22

Dyne Therapeutics announces $300M common stock offering

TIPRANKS
·
Jul 22

Dyne Therapeutics Launches USD 300 Million Common Stock Offering

Reuters
·
Jul 22

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jul 22

Should FDA Priority Review of Dyne’s DMD Drug Candidate Reshape Risk Expectations for Dyne Therapeutics (DYN) Investors?

Simply Wall St.
·
Jul 21

Dyne Therapeutics Advances DYNE-251 With FDA Priority Review

TIPRANKS
·
Jul 20

Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA

TIPRANKS
·
Jul 20

Dyne Says FDA Accepts Z-rostudirsen BLA for Exon 51 Duchenne Muscular Dystrophy Under Priority Review

Reuters
·
Jul 20

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (bla) for Z-rostudirsen in Exon 51 Duchenne Muscular Dystrophy (dmd)

THOMSON REUTERS
·
Jul 20

Dyne Therapeutics, Inc: Continues to Expect a Potential U.S. Launch of Z-rostudirsen in Q1 2027

THOMSON REUTERS
·
Jul 20

Dyne Therapeutics, - FDA Grants Priority Review with Pdufa Date January 21, 2027

THOMSON REUTERS
·
Jul 20

Insider Move at Dyne Therapeutics Sparks Fresh Investor Buzz

TIPRANKS
·
Jul 09

Dyne Therapeutics Director Jason P. Rhodes Reports Sale of 777,451 Shares Worth USD 17.83 Million

Reuters
·
Jul 09

Guggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 01

Dyne Therapeutics Director Jason P. Rhodes Disposes of Common Shares Worth $10.66 Million

Reuters
·
Jul 01

Top Executive’s Sudden Stock Move Sends a Fresh Signal to Dyne Investors

TIPRANKS
·
Jun 27

Dyne Therapeutics Director Jason P. Rhodes Reports $5.15 Million Common Share Disposal

Reuters
·
Jun 26

Dyne Therapeutics, Inc : TD Cowen Initiates Coverage with Buy Rating

THOMSON REUTERS
·
Jun 26